XTALPI (02228) saw its stock soar by 5.16% in intraday trading on Thursday, following the release of a significant report by KPMG on the biotech industry. The surge comes as investors react to the growing importance of artificial intelligence (AI) in drug development, a field where XTALPI is positioned as a key player.

KPMG's "Third Report on Leading 50 Enterprises in Biotech Innovation" emphasizes that AI has now permeated every aspect of drug development. The report highlights how AI is being utilized across all phases, from drug target discovery and synthetic pathway optimization to clinical trial design. Notably, in precision medicine, AI has evolved beyond being just an assistive tool, with deep neural network models now improving gene editing accuracy from about 85% in traditional methods to over 98%. This breakthrough is seen as clearing a major hurdle for the clinical translation of gene therapy.

As one of the companies specifically mentioned in the KPMG report, XTALPI's stock rally reflects growing investor confidence in AI-driven drug discovery platforms. The company's AI-powered technologies for accelerating drug discovery and development processes appear to be well-aligned with the industry trends highlighted in the report. This positive sentiment, coupled with the broader implications of AI advancements in the biotech sector, likely contributed to the significant uptick in XTALPI's stock price during the trading session.